Search research articles
Contact Us
Filters
Showing results (111-120 of 123) with videos related to
Page
of 13
Sort By:
The American Journal of Surgical Pathology
|
November 26, 2019
Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model
Masato Nakaguro, Yukiko Sato, Yuichiro Tada, et al.
Frontiers in Surgery
|
December 1, 2022
Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutions
Hiroshi Matsuyama, Yushi Ueki, Isaku Okamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2022
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
Naomi Kiyota, Makoto Tahara, Junki Mizusawa, et al.
Oral Oncology
|
August 7, 2024
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008
Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, et al.
Oral Oncology
|
April 19, 2025
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy
Satoshi Kano, Daisuke Kawakita, Yoshitaka Honma, et al.
Frontiers in Oncology
|
February 21, 2022
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy
Natsuki Saigusa, Hideaki Hirai, Yuichiro Tada, et al.
NPJ Precision Oncology
|
November 5, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling
Shinji Kohsaka, Yuichiro Tada, Mizuo Ando, et al.
Therapeutic Advances in Medical Oncology
|
September 12, 2022
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, et al.
Auris, Nasus, Larynx
|
January 21, 2026
Transoral surgery for hypopharyngeal and laryngeal cancers in Japan: Current status from a nationwide multicenter retrospective study
Koji Araki, Seiichi Yoshimoto, Takashi Fujii, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 123) with videos related to
Sort By:
Page
of 13
The American Journal of Surgical Pathology
|
November 26, 2019
Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model
Masato Nakaguro, Yukiko Sato, Yuichiro Tada, et al.
Frontiers in Surgery
|
December 1, 2022
Head and neck small-cell carcinoma: A multicenter study of 39 cases from 10 institutions
Hiroshi Matsuyama, Yushi Ueki, Isaku Okamoto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2026
Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2022
Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial
Naomi Kiyota, Makoto Tahara, Junki Mizusawa, et al.
Oral Oncology
|
August 7, 2024
Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008
Hidetoshi Shimizu, Takeshi Kodaira, Naomi Kiyota, et al.
Oral Oncology
|
April 19, 2025
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy
Satoshi Kano, Daisuke Kawakita, Yoshitaka Honma, et al.
Frontiers in Oncology
|
February 21, 2022
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy
Natsuki Saigusa, Hideaki Hirai, Yuichiro Tada, et al.
NPJ Precision Oncology
|
November 5, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profiling
Shinji Kohsaka, Yuichiro Tada, Mizuo Ando, et al.
Therapeutic Advances in Medical Oncology
|
September 12, 2022
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma
Daisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, et al.
Auris, Nasus, Larynx
|
January 21, 2026
Transoral surgery for hypopharyngeal and laryngeal cancers in Japan: Current status from a nationwide multicenter retrospective study
Koji Araki, Seiichi Yoshimoto, Takashi Fujii, et al.
Page
of 13